Arcutis Biotherapeutics (NASDAQ:ARQT) executives highlighted strong recent commercial performance for ZORYVE and outlined near-term regulatory and pipeline milestones during a presentation and fireside chat at TD Cowen’s 46th Annual Healthcare Conference.
Q4 performance and 2025 results
Chief Executive Officer Frank Watanabe said the company delivered a “very strong” fourth quarter and full-year 2025, pointing to $127.5 million in fourth-quarter net revenue and $372 million for the year. Watanabe said the fourth-quarter result was above consensus expectations, and he also emphasized that the company “effectively” doubled prescriptions in 2025.
Commercial strategy: steroid conversion, sales force expansion, and payer coverage
Management repeatedly framed ZORYVE’s growth opportunity as a conversion story away from topical steroids. Edwards cited data showing 24 million topical prescriptions written in dermatology for the three inflammatory skin diseases where ZORYVE is indicated, with topical steroids representing 64% of prescriptions and nonsteroidal topicals at 7%—up from about 4% a few quarters earlier. He said ZORYVE holds a leading share within the nonsteroidal topical market and is capturing a large portion of that market’s growth.
In response to questions about demand durability going into 2026, Edwards said the company saw robust new prescription growth in the fourth quarter and plans to expand its dermatology sales force by 30 representatives, reaching 160 dermatology reps. He said the purpose is to increase call frequency on mid-decile prescribers while maintaining frequency with high-decile prescribers.
Watanabe also noted the company is ending its primary care partnership and bringing those efforts in-house, building dedicated primary care and pediatric sales capabilities alongside the dermatology team. Edwards said Arcutis aims to have both the dermatology expansion and an initial 30-person primary care/pediatrics team hired, onboarded, and in the field by July 1. He said dermatology productivity typically shows impact in about three months, while primary care and pediatrics may take longer, likely into the back half of the year. Watanabe characterized the initial primary care build as a “pilot” that will cover a targeted subset of providers and can be scaled if accretive.
On payer access, Edwards said the company has “exceptional” commercial coverage, often with a single-step steroid requirement. He said about half of Medicaid beneficiaries have access through a single step. Watanabe and Edwards highlighted a Medicare development: Arcutis picked up access to about one-third of Medicare lives and said ZORYVE is the only branded topical on the Medicare formulary. Edwards said the company expects opportunities to add additional Medicare coverage beginning January 1, 2027, with a possibility of pulling some access forward into 2026, depending on contracting cycles.
Product mix and pediatric opportunities
Edwards described current portfolio mix, saying ZORYVE foam represents about 50% of the business, supported by indications including seborrheic dermatitis and scalp/body psoriasis and what he called a highly differentiated formulation. He said ZORYVE cream 0.3% for psoriasis and the two atopic dermatitis products (0.15% and 0.5%) are “about equal,” and management expects growth across all SKUs, with continued strength in foam and “robust” growth in atopic dermatitis given the size of that market.
Watanabe discussed pediatric expansion, saying Arcutis expects approval in plaque psoriasis for ages 2–5 by the end of June and plans to file an NDA in the second quarter for atopic dermatitis in 3–24-month-old patients based on the INTEGUMENT infant trial. He said pediatric psoriasis is relatively uncommon and may not be a major standalone catalyst, but could support a broader “halo” effect around safety perceptions. He emphasized the opportunity in infant atopic dermatitis, noting few FDA-approved options for that age group aside from topical steroids, and said physicians have shown strong interest following the release of top-line data.
Pipeline: new ZORYVE studies and ARQ-234
Watanabe said the company is evaluating additional uses for ZORYVE beyond its current approvals, with ongoing Phase II studies in hidradenitis suppurativa (HS) and vitiligo. He cited published case series that he said were encouraging, including reports of pediatric facial vitiligo patients who had failed topical steroids and responded to ZORYVE, and an HS case series that showed rapid responses within four weeks. Arcutis expects a vitiligo readout in Q4 of this year and plans to decide then whether to advance to Phase III; it expects results from a key HS study in Q1 next year with a similar Phase III decision point. Watanabe also said the company may start additional proof-of-concept studies in other diseases this year.
Separately, Watanabe highlighted ARQ-234, which he described as a novel approach for atopic dermatitis by agonizing an immune checkpoint (CD200). He said the target is only expressed on activated immune cells and could potentially normalize immune responses without immunosuppression. He cited data from another company’s work on the same target that suggested improvements could persist after dosing stops, indicating possible remission, and said Arcutis expects to have ARQ-234 in the clinic this quarter.
Competition, intellectual property, and cash flow
Asked about competition, Watanabe said he views the market as “a marketplace of two products” and said he was not concerned about a recently approved competitor PDE4 inhibitor, contrasting it with roflumilast on potency, dosing, formulation, breadth of indications, and commercial footprint in dermatology.
On intellectual property, Watanabe said the company has 27 issued U.S. patents covering ZORYVE. He said patent coverage extends through 2042 for the foam and 2037 for the cream. He also discussed an ANDA filer from about two years ago that encountered FDA issues and agreed to toll Hatch-Waxman litigation timing during a stay; he said Arcutis would restart litigation if the program resumes and expressed confidence in prevailing.
Financially, Watanabe said Arcutis reached cash flow breakeven in the prior quarter and expects to maintain quarterly cash flow breakeven going forward, including ongoing lifecycle management and development of ARQ-234. He said the company added $26 million of cash to the balance sheet last quarter and described its cash runway as effectively “infinite” absent significant business development. While he said profitability may fluctuate due to non-cash items, he emphasized cash flow discipline.
In closing comments, Watanabe said he believes investors may be underappreciating the long-term potential of ZORYVE and the value of the pipeline, while Edwards pointed again to the size of the steroid conversion opportunity as a key driver.
About Arcutis Biotherapeutics (NASDAQ:ARQT)
Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.
In August 2022, Arcutis received U.S.
See Also
- Five stocks we like better than Arcutis Biotherapeutics
- New Copper-Rich “Kraken” Zone Discovered
- America’s 1776 happening again
- 3 Signs You May Want to Switch Financial Advisors
- Silver’s squeeze is tightening – opportunity forming
- Trump’s NEW Executive Order – BIG Changes Coming to Retirement Accounts
